Divis Laboratories Ltd (DIVISLAB)
Healthcare · Pharmaceuticals · NSE · Updated 1 October 2026
₹9,475↑ 66.59% (1Y)
🎯 Key Takeaways
- Revenue grew 8.8% QoQ to ₹3,080 in Q1FY27.
- Market Cap
- ₹2.52 L Cr
- P/E Ratio
- 86.0
- P/B Ratio
- 15.01
- ROE
- 17.4%
- ROCE
- 23.0%
- Debt/Equity
- 0.00
- Div Yield
- 0.32%
- Promoter
- 51.9%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 2,715 | 2,604 | 2,831 | 3,080 |
| Operating Profit | 775 | 772 | 814 | 1,122 |
| OPM % | 28.6% | 29.6% | 28.8% | 36.4% |
| Net Profit | 689 | 583 | 751 | 902 |
| EPS | ₹25.97 | ₹21.98 | ₹28.31 | ₹33.95 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 53 | 53 | 53 | 53 |
| Reserves | 14,916 | 13,664 | 16,708 | 15,360 |
| Borrowings | 4 | 8 | 0 | 90 |
| Total Liabilities | 16,932 | 15,586 | 20,033 | 18,151 |
| Fixed Assets | 5,438 | 4,654 | 6,528 | 5,674 |
| Investments | 65 | 85 | 69 | 67 |
| Total Assets | 16,932 | 15,586 | 20,033 | 18,151 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +2,738 |
| Investing | -2,219 |
| Financing | -804 |
| Net Cash Flow | -285 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 51.9% | 51.9% | 51.9% | 51.9% |
| FII | 19.4% | 20.1% | 20.3% | 20.2% |
| DII | 19.8% | 19.3% | 19.2% | 19.4% |
| Public | 6.8% | 6.6% | 6.5% | 6.4% |
| # Shareholders | 2,49,634 | 2,33,844 | 2,28,006 | 2,26,324 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- Announcement2026-09-30Divis Laboratories announced that its trading window will close on October 1, 2026, ahead of the unaudited quarterly results for the September 2026 qu…
- 🟡 Board Meeting2026-08-10Divi's Laboratories held its 36th AGM on August 10, 2026, via video conferencing, where shareholders approved all resolutions including the reappointm…
- 🔴 Financial Results2026-08-06Divi's Laboratories reported consolidated revenue of ₹3,144 crores and profit after tax of ₹902 crores for Q1 FY27, up 10% in constant currency YoY. E…
- 🟡 Board Meeting2026-08-01Divi's Laboratories reported unaudited standalone financial results for Q1 FY2026 ending June 30, 2026, showing total income of **₹3,037 crores**, pro…
- Announcement2026-08-01Divi's Laboratories announced its August 1, 2026 board meeting outcomes, approving unaudited standalone and consolidated financial results for Q1 FY20…
- Announcement2026-08-01Divi's Laboratories announced that the audio recording of its Q1 FY27 earnings conference call held on August 1, 2026, is now available on its investo…
- Announcement2026-07-31Divi's Laboratories announced the retirement of two senior executives, Vice President of Procurement L. Ramesh Babu and Vice President of Projects D. …
- Announcement2026-07-24Divi's Laboratories announced its Q1 FY27 earnings conference call on August 1, 2026, at 14:00 IST following the release of unaudited results for the …
- share transfer2026-07-07Divi's Laboratories submitted a SEBI-mandated certificate from its share transfer agent KFin Technologies for the quarter ended June 30, 2026, confirm…
- 🟡 concall transcript2026-06-30Divi's Laboratories reported standalone revenue of ₹3,037 crores for Q1 FY27 (ended June 30, 2026), up 10% in constant currency, with profit after tax…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when DIVISLAB files new disclosures
Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DIVISLAB — FreeFree account · 2 AI queries/day